Stockscreener 앱 받기
1.87
0.54%
0.01
시간 외 거래:
1.80
-0.07
-3.74%
전일 마감가:
$1.86
열려 있는:
$1.88
하루 거래량:
27,904
Relative Volume:
0.41
시가총액:
$6.67M
수익:
-
순이익/손실:
$-11.89M
주가수익비율:
-0.332
EPS:
-5.6317
순현금흐름:
$-10.96M
1주 성능:
-4.10%
1개월 성능:
-22.73%
6개월 성능:
-66.21%
1년 성능:
-85.53%
1일 변동 폭
$1.79
$1.9139
1주일 범위
$1.76
$2.12
52주 변동 폭
$1.76
$14.64
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
명칭
Cadrenal Therapeutics Inc
전화
904-300-0701
주소
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
1.87 | 6.56M | 0 | -11.89M | -10.96M | -5.6317 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-18 | 개시 | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Avoiding Lag: Real-Time Signals in (CVKD) Movement - Stock Traders Daily
Cadrenal Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price Target - TipRanks
PNC Financial Services Group, Inc. Acquires New Stake in Cadrenal Therapeutics Inc (CVKD) - GuruFocus
Cadrenal Therapeutics Q2 Results: Net Loss Narrows To $3.3 Million - scanx.trade
Cadrenal Therapeutics reports Q2 2026 net loss of $3.3M; cash runway into Q1 2027 - TradingView
Cadrenal CAD-1005 data show more than 25% absolute drop in clot events - Stock Titan
Cadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a shareEarnings Preview - TradingView
Cadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client - Stock Titan
CVKD | Cadrenal Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Cadrenal Therapeutics (CVKD) Slips 2.49% to $1.96 as Shares Test Range-Bound SupportAI Trade Signals - dars.gov.et
CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy - Smartkarma
Cadrenal expands CAD-1005 development to two indications - Investing.com
Cadrenal expands CAD-1005 development to two indications By Investing.com - Investing.com India
Cadrenal Therapeutics Highlights CAD-1005 as Dual-Indication 12-LOX Inhibitor for HIT and CSA-AKI Following Competing Trial Failure - Quiver Quantitative
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation - Yahoo Finance
Cadrenal Therapeutics announces annual shareholder meeting - Bitget
Cadrenal Therapeutics (CVKD) Drops 3.8%, Approaches Critical $1.91 SupportSentiment Divergence - dars.gov.et
Cadrenal Therapeutics Inc (CVKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cadrenal Therapeutics Inc (CVKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:1.830|Chg%:-0.030 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cadrenal Therapeutics Inc (CVKD) Institutional Confidence - TradingKey
Cadrenal Therapeutics Inc (CVKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:2.045|Chg%:-0.015 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
TradingKey - TradingKey
Cadrenal Therapeutics Inc (CVKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cadrenal Therapeutics Market Sentiment - Benzinga España
Cadrenal Therapeutics, Inc. Revenue Breakdown – NASDAQ:CVKD - TradingView
CVKD|Cadrenal Therapeutics Inc|Price:2.030|Chg%:-0.010 - TradingKey
Form PRE 14A CADRENAL THERAPEUTICS For: 23 July By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (NASDAQ: CVKD) seeks approval for 1M-share equity plan and 960K warrant shares - Stock Titan
H.C. Wainwright Maintains Cadrenal Therapeutics(CVKD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cadrenal seeks partners for cardiac care drug portfolio By Investing.com - Investing.com South Africa
Cadrenal Therapeutics, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
Cadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy - TipRanks
Cadrenal seeks partners for cardiac care drug portfolio - Investing.com
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation - The Manila Times
Cadrenal Therapeutics Launches Partnering Process as Its - GlobeNewswire
Cadrenal Therapeutics Announces Chief Medical Officer Transition - The Globe and Mail
Cadrenal Therapeutics (NASDAQ: CVKD) outlines CMO Ferguson's exit deal - Stock Titan
Cadrenal Therapeutics (CVKD) Edges Lower Amid Mixed Sentiment, Holding Above Key SupportBollinger Expansion - po-news-eg.net
Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing - Stock Titan
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
CADRENAL THERAPEUTICSNO SERIOUS ADVERSE EVENTS OR DEATHS REPORTED WITH CAD-1005 IN PHASE 2 TRIAL - webull.com
Form S-3 Cadrenal Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (NASDAQ: CVKD) files resale for 2.94M warrant shares - Stock Titan
Cadrenal presents phase 2 data for CAD-1005 at ISTH congress - Investing.com Nigeria
Cadrenal presents phase 2 data for CAD-1005 at ISTH congress By Investing.com - Investing.com South Africa
Cadrenal Therapeutics Inc (CVKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):